PHARMACOKINETICS OF BOWMAN-BIRCK INHIBITOR FROM Macrotyloma axillare

SANTOS A. G. (1), FONSECA T. B. W. (1), SILVA K. T. S. (1), GOUVEIA DOS SANTOS, R. (2), ANDRADE M. H. G. (1)

(1) Lab de Enzimologia e Biofísica- ICEB/NUPEB/Universidade Federal de Ouro Preto, (2) Lab. Radiobiologia, Centro de Desenvolvimento da Tecnologia Nuclear/CNEM, Belo Horizonte, MG

There are crowing evidences that dietary factors have a tight correlation with different kinds of cancer development. Among the compounds of diet related with cancer development prevention, we could mention the Bowman-Birk Inhibitors. Our group have isolated Bowman-Birk Inhibitors (BBI) from Macrotyloma axillare showing high specific inhibitory activities over bovine trypsin and chymotrypsin enzymes, specially from the germinated seeds. In order to study their pharmacokinetics parameters, we radiolabeled Macrotyloma and Soybean BBI’s, which are by the way, the most studied inhibitors of this class. Macrotyloma axillare inhibitors got widely distributed over Swiss mice organs, but they shown an important difference in comparison with soybean inhibitor biodistribution, which is a meaning bigger affinity for the stomach.  Macrotyloma inhibitor have a distribution volumes of approximately four folds the plasmatic volume and half-life of 14,4 and 7 hours for seed and germinated seed BBI respectively. When applied in isolated intestinal loops of Swiss mice, soybean inhibitors get to almost 50% of bioavailability, while Macrotyloma axillare inhibitors from seeds and cotyledons get to 30 and 40% respectively. Meanwhile the biggest potency of cotyledons inhibitor of Macrotyloma makes available a bigger activity (approximately nine folds) then soybean inhibitors do.

KEY WORDS: Bowman-Birk, Cancer, Phamacokinetic

FINANCIAL SUPPORT: CNPq, FAPEMIG

CORRESPONDENCE TO: mguerra@nupeb.ufop.br